UAE: 96% children developed antibodies after Sinopharm shots

More than 96 per cent of children who took part in the UAE's Sinopharm vaccine trial developed antibodies to fight COVID-19.

Also, no major side effects were reported in the 900 young volunteers, aged 3-17.

The details were revealed during the government's latest media briefing on Tuesday.

Officials said 29.7 per cent had pain at the injection site, 8 per cent had a headache, while 3.7 per cent had a fever.

Earlier this month, the UAE gave its approval for using Sinopharm vaccine in children aged 3-17.

During the latest briefing, Dr. Noura Al Ghaithi, Acting Chief Executive Officer of Ambulatory Healthcare Services at SEHA, also reiterated the benefits of getting vaccinated.

From January 1- July 23, eight out of 10 people who were hospitalised due to COVID-19 were found to be unvaccinated, while nine out of 10 unvaccinated patients were sent to intensive care.